Interchangeability: When Biosimilars Can Be Substituted Automatically

When you fill a prescription for a biologic drug like Humira or Enbrel, you might not realize that a cheaper version could be sitting on the shelf - and your pharmacist might swap it in without asking. That’s not a mistake. It’s interchangeability, a legal and regulatory tool in the U.S. that lets pharmacists automatically replace a brand-name biologic with a biosimilar - no doctor’s approval needed. But here’s the catch: not all biosimilars can do this. Only a handful have earned the FDA’s special interchangeability designation, and even then, whether you get swapped depends on where you live.

What’s the difference between a biosimilar and a generic?

Generics are copies of small-molecule drugs like ibuprofen or metformin. They’re chemically identical to the original. A generic pill has the same active ingredient, the same structure, the same way it works in your body. That’s why pharmacists can swap them without hesitation.

Biosimilars are different. They’re copies of biologic drugs - complex proteins made from living cells, not chemicals. Think insulin, rheumatoid arthritis treatments, or cancer drugs. Because they’re made by living systems, no two batches are exactly alike. Even slight changes in how they’re made can affect how they behave in your body. That’s why the FDA doesn’t call them generics. They’re called biosimilars - meaning they’re highly similar, but not identical.

Here’s the key point: all FDA-approved biosimilars are as safe and effective as the original. But only some are designated as interchangeable. That’s the only status that lets pharmacists switch them out automatically.

How does interchangeability work in the U.S.?

The U.S. is the only country in the world with a formal interchangeability pathway for biosimilars. It was created by the Biologics Price Competition and Innovation Act (BPCIA) in 2010. To earn this status, a biosimilar maker must prove more than just similarity. They need to show that switching back and forth between the original drug and the biosimilar doesn’t increase risk or reduce effectiveness.

The FDA requires at least two switches in clinical studies - for example, a patient takes the brand drug, then switches to the biosimilar, then switches back again. Researchers track things like immune response, side effects, and how the drug behaves in the bloodstream. If the data shows no clinically meaningful differences after multiple switches, the FDA grants interchangeability.

As of November 2023, the FDA has approved 41 biosimilars. Only 10 of them have interchangeability status. The first was Semglee (insulin glargine-yfgn), approved in July 2021. The first interchangeable monoclonal antibody was Cyltezo (adalimumab-adbm), approved in August 2023. These are big deals - insulin and adalimumab are among the most prescribed biologics in the country.

State laws make substitution a patchwork

Even if a biosimilar is FDA-interchangeable, your pharmacist might not be allowed to swap it. That’s because each state has its own rules.

• 40 states, including Arizona and California, let pharmacists substitute without asking - as long as the drug is designated interchangeable and the prescriber hasn’t blocked it.
• 6 states and Washington D.C. only allow substitution if it saves the patient money.
• 4 states - Alabama, Indiana, South Carolina, and Washington - require the prescriber to approve the switch in advance.

Pharmacists have to juggle these rules every day. A pharmacist in New York might swap a biosimilar without telling you. One in Alabama can’t do it unless the doctor says so. And if you get your prescription filled in a different state - say, while traveling - the rules change again.

There’s also a reporting requirement. In most states, pharmacists must notify the prescriber within a few days, keep records for up to seven years, and document exactly which product was dispensed. Some states even require the patient to be informed in writing.

Why does this matter to patients?

Interchangeability is meant to cut costs. Biosimilars typically cost 15-30% less than the original biologic. For insulin, that can mean saving $800 a month - a life-changing difference for someone without good insurance.

But there are risks. Some patients report issues after being switched without warning. One patient on a psoriasis forum described an allergic reaction after their pharmacy automatically substituted a biosimilar. Turns out, they were sensitive to an inactive ingredient (an excipient) in the new version. The original drug didn’t have it.

A 2022 survey by the National Psoriasis Foundation found that 63% of patients were satisfied with their biosimilar, but 28% were worried they weren’t told about the switch. Transparency matters. If you’re stable on a drug, a sudden change - even to an FDA-approved alternative - can cause anxiety or side effects.

Studies show that non-medical switching can lead to higher discontinuation rates. One study in psoriasis patients found a 20.3% higher chance of stopping treatment after being switched to a biosimilar. That doesn’t mean biosimilars are unsafe - it means sudden changes without patient input can disrupt care.

What’s happening right now?

The market is shifting fast. In Q2 2023, biosimilars made up 34% of the volume of insulin and adalimumab prescriptions in the U.S., but only 22% of the revenue - because they’re cheaper. Semglee, the first interchangeable insulin, grabbed 17.3% of the market within six months. Non-interchangeable biosimilars took only 9.8% in the same time.

Insurance companies are pushing for automatic substitution. About 78% of commercial health plans now require it when state law allows. That means even if you prefer the brand, your insurer may block coverage unless you get the biosimilar.

Meanwhile, lawmakers are debating whether to eliminate the switching studies entirely. The Biosimilar Red Tape Elimination Act, introduced in 2022, would make every FDA-approved biosimilar interchangeable by default. Supporters say it’s needed to drive down prices. Critics, including PhRMA, warn it could compromise safety.

What should you do?

• Ask your doctor: Is my biologic eligible for a biosimilar? Is it interchangeable?
• Ask your pharmacist: Will you substitute? Do I need to sign anything? Will I be notified?
• Check your state’s law. You can find it through your state pharmacy board’s website.
• Keep track of what you’re taking. Note the manufacturer name on the bottle. If your drug changes unexpectedly, call your prescriber.
• If you’re stable and doing well, ask to stay on your current drug. Prescribers can block substitution with a "dispense as written" note or a DAW code on the prescription.

The goal of interchangeability is to make life-saving drugs more affordable. But it’s not a one-size-fits-all solution. It works best when patients are informed, pharmacists are trained, and doctors are part of the decision.